Based on the above results, we speculated that the gut microbiome changes affect the expression of immune-related cytokines IFN-γ and IL-2 in the tumor microenvironment, resulting in a different therapeutic effect of PD-1 antibody. This evidence concerns the gene PDCD1 and neoplasm.